Comparative Pharmacology
Head-to-head clinical analysis: BLUDIGO versus ISOSULFAN BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLUDIGO versus ISOSULFAN BLUE.
BLUDIGO vs ISOSULFAN BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
Isosulfan blue is a dye that binds to serum proteins after intradermal injection, allowing visualization of lymphatic channels and lymph nodes during sentinel lymph node biopsy. It has no known pharmacological activity beyond its use as a visual contrast agent.
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
1-2 mL (10-20 mg) of a 1% solution injected subcutaneously or intradermally around the tumor or into the tumor, typically 3-5 minutes prior to sentinel lymph node biopsy.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life is approximately 20-30 minutes. Clinically, the dye is rapidly cleared from the plasma, which correlates with its short duration of action as a lymphographic agent.
Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%.
Primarily excreted unchanged in bile via the hepatobiliary system (approximately 90%). Renal excretion accounts for less than 10% of the administered dose.
Category C
Category C
Diagnostic Dye
Diagnostic Dye